X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal, Dogmatil, Largactil.
Lead Product(s): Levomepromazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Nozinan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neuraxpharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 01, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of severe chronic pain.
Lead Product(s): Levomepromazine Maleate
Therapeutic Area: Psychiatry/Psychology Product Name: Nozinan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neuraxpharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 12, 2022
Iran Expo
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
